Dibrompropamidine is a topical antimicrobial drug belonging to the diamidine group of compounds, developed during the mid-20th century when synthetic antiseptics were being widely researched to combat infectious diseases. Introduced alongside related agents such as Propamidine and Pentamidine, it became recognized for its antibacterial and antiprotozoal properties. Formulated mainly as dibrompropamidine isethionate, the drug has been used primarily in ophthalmology for treating minor eye infections such as conjunctivitis and superficial keratitis, as well as certain mild skin infections. Its mechanism of action involves disrupting microbial cell membranes and interfering with essential cellular functions, making it effective against some bacteria and protozoa, including Acanthamoeba species. Over the decades, dibrompropamidine has maintained its place in clinical practice particularly in Europe due to its established safety profile, over-the-counter availability in some regions, and continued usefulness in managing mild, localized infections despite the development of newer antimicrobial agents.
